The focus of a recent FDA’s Psychopharmacology Advisory Committee meeting, was the drug, modafinil (as Sparlon), for ADHD and the risk of
Steven-Johnson’s, a rare but potentially fatal, skin condition.
On Wednesday, the FDA Pediatric Advisory Committee handed the agency a mixed message regarding warnings about selective list of
psychotropic drugs prescribed for treating ADHD symptoms.
Below a press release from the lawfirm, Baum Hedlund, announces it has filed a class action lawsuit against GlaxoSmithKline charging the company with fraud, negligence, strict liability, and breach of warranty in its marketing of Paxil (Seroxat) by concealing the risk of suicide.
AHRP Urges Actions to Minimize Risks for Children prescribed psychotropic drugs: Action is needed to protect children from widespread prescribing of psychoactive drugs for ill-defined behavioral symptoms.
"Biological psychiatrists have looked very closely for a serotonin imbalance or dysfunction in patients with depression or obsessive compulsive disorder and, to date, it has been elusive," says Dr. Wayne Goodman, Chair of the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee.
The Arkansas Democrat Gazette reports (below): "TeenScreen, developed by a Columbia University professor, has come under intense criticism nationally."
The Boston Globe reports (below): “More than 50 years after psychiatrists began widely dispensing drugs to treat mental illness, the profession is coming face to face with a humbling reality: Its treatments often fail, leaving millions of patients [ ] to suffer while doctors search for something that works.”
Mental Screening ties to drug companies exposed. Screening for Mental Health (Harvard affiliated) received $500K from Eli Lillly. See: https://ahrp.org/children/mentalscreen/LillyCheck.jpg
TeenScreen hired high powered PR firms whose business is to create promotional campaigns to increase drug sales for its clients.
An analysis published in the current issue of the British J of Psychiatry (BJP) of the suicide rate among schizophrenia patients treated at the same hospital in North Wales (UK) before psychotropic drugs and patients treated (in and out of hospital) with neuroleptics and /or atypical antipsychotics, found a 20-fold increase in the suicide rate since use of psychotropic drugs.
It is no longer possible not to notice the lack of medical justification for current psychotropic drug prescribing practices.
"This is out-of-control use of drugs that have profound cardiovascular consequences. We have got a potential public health crisis. I think patients and families need to be made aware of these concerns."
Children have been dying from exposure to psychostimulant drugs as the FDA looked the other way:
